About That Finding…

Medical studies that show large effects often don't hold up under further scrutiny, a new paper published in the Journal of the American Medical Association says. Stanford University's John Ioannidis and his colleagues analyzed clinical trial data from the Cochrane Database of Systematic Reviews and found that "when additional evidence is obtained, most of the very large treatment effects become much smaller and many lose their nominal significance," the authors write.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.